All In Biotech

Free tool

FAERS Monitor: Semglee

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 210605 or its brand name (Semglee, Insulin Glargine). Reports on generic versions are filed under their own applications.

Reports

367

Serious

188

51% of reports

Hospitalization

104

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • device issue38
  • nausea30
  • product dose omission issue26
  • product quality issue26
  • diarrhoea24
  • blood glucose increased21
  • dyspnoea19
  • drug ineffective17
  • fatigue17
  • headache17
  • hypoglycaemia16
  • pain16
  • vomiting16
  • asthenia13
  • weight decreased13

Reports by year received

View as table
YearReports
202021
202142
202241
202346
202475
202589
202653

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,792 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device issueSignal3824.318.0829
hypoglycaemiaSignal1618.911.7254
product quality issueSignal2611.07.6227
blood glucose increasedSignal216.44.291
product dose omission issueSignal265.13.582
weight decreasedSignal132.71.612
nauseaSignal302.21.519
diarrhoeaSignal242.11.414
asthenia132.01.25
vomiting162.01.27
dyspnoea191.91.28
headache171.61.03
pain161.50.92
fatigue171.30.81
drug ineffective170.70.51

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.